Shanyunlong

Dr. Yunlong Shan is a respectable associate professor of pharmacokinetics and pharmacology at China Pharmaceutical University, with a profound commitment to advancing our understanding of the immunology between gut microbiota and human body. Holding a Ph.D in Pharmacy from Nanjing University. Dr. Shan specializes in immunometabolism and live biotherapeutic product (LBP).

He is presiding 6 important projects funded by the National Natural Science Foundation and provincial-level authorities, publishing multiple SCI papers and patents as first author or   corresponding author in top journals such as Acta Pharmaceutica Sinica B, Cell Death & Disease, Phytomedicine and Stem Cell Research & Therapy over the past few years.

Dr. Shan is also a key member of the third “National Innovation Forefront Award” and has delivered video presentations at international academic conferences of ASCO (American Society of Clinical Oncology) in 2021.

Dr. Shan serves as the youth editorial board member of the Journal of China Pharmaceutical University and iMeta. In addition, Dr. Shan also act as a reviewer for journals including Immunology, Phytomedicine, mSystems and Stem Cell Research & Therapy.

1. “Mesenteric lymph nodes: a critical site for the up-regulatory effect of hUC-MSCs on Treg cells by producing TGF-β1 in colitis treatment” Published in the journal of Stem Cell Research & Therapy, 2024

2. “Targeting tumor endothelial hyperglycolysis enhances immunotherapy through remodeling tumor microenvironment” Published in the journal of Acta Pharmaceutica Sinica B, 2021

3. “Synthetic lethality theory approaches to effective substance discovery and functional mechanisms elucidation of anti-cancer phytomedicine” Published in the journal of Phytomedicine, 2021

4. “Anlotinib enhanced penpulimab efficacy through remodeling of tumor vascular architecture and immune microenvironment in hPD-L1/hPD-1 humanized mouse model” Published in the journal of Journal of Clinical Oncology, 2021

5. “Targeting HIBCH to reprogram valine metabolism for the treatment of colorectal cancer” Published in the journal of Cell Death & Disease, 2019

6. “Preclinical development of GR1501, a human monoclonal antibody that neutralizes interleukin-17A” Published in the journal of Biochemical and Biophysical Research Communications, 2019

7. “Diallyl trisulfides, a natural histone deacetylase inhibitor, attenuate HIF-1α synthesis, and decreases breast cancer metastasis” Published in the journal of Molecular Carcinogenesis, 2017

8. “Prophylaxis of Diallyl Disulfide on Skin Carcinogenic Model via p21-dependent Nrf2 stabilization” Published in the journal of Scientific Reports, 2016

1.A study about the molecular mechanism of mesenchymal stemcell-derived IL4Ⅰ1 as metabolic modulator for the immunologic balanceof psoriasis.

2.MSCs synergistically regulate mitophagy to promote spiral ganglion neuron repair mechanisms and intervention strategies for restoring auditory function.

National Innovation Forefront Award

1.Methods and Techniques in Angiogenesis Research

2.Methodology of Traditional Chinese Medicine Pharmacological Research, CHAPTER 2

3.Methodology of Traditional Chinese Medicine Pharmacological Research, CHAPTER 5